BACKGROUND AND PURPOSE: The antidepressant efficacy of selective 5-HT reuptake inhibitors (SSRI) and other 5-HT-enhancing drugs is compromised by a negative feedback mechanism involving 5-HT(1A) autoreceptor activation by the excess 5-HT produced by these drugs in the somatodendritic region of 5-HT neurones. 5-HT(1A) receptor antagonists augment antidepressant-like effects in rodents by preventing this negative feedback, and the mixed β-adrenoceptor/5-HT(1A) receptor antagonist pindolol improves clinical antidepressant effects by preferentially interacting with 5-HT(1A) autoreceptors. However, it is unclear whether 5-HT(1A) receptor antagonists not discriminating between pre- and post-synaptic 5-HT(1A) receptors would be clinically effective. EXPERIMENTAL APPROACH: We characterized the pharmacological properties of the 5-HT(1A) receptor antagonist DU-125530 using receptor autoradiography, intracerebral microdialysis and electrophysiological recordings. Its capacity to accelerate/enhance the clinical effects of fluoxetine was assessed in a double-blind, randomized, 6 week placebo-controlled trial in 50 patients with major depression (clinicaltrials.gov identifier NCT01119430). KEY RESULTS:DU-125530 showed equal (low nM) potency to displace agonist and antagonist binding to pre- and post-synaptic 5-HT(1A) receptors in rat and human brain. It antagonized suppression of 5-hydroxytryptaminergic activity evoked by 8-OH-DPAT and SSRIs in vivo. DU-125530 augmented SSRI-induced increases in extracellular 5-HT as effectively as in mice lacking 5-HT(1A) receptors, indicating a silent, maximal occupancy of pre-synaptic 5-HT(1A) receptors at the dose used. However, DU-125530 addition to fluoxetine did not accelerate nor augment its antidepressant effects. CONCLUSIONS AND IMPLICATIONS: DU-125530 is an excellent pre- and post-synaptic 5-HT(1A) receptor antagonist. However, blockade of post-synaptic 5- HT(1A) receptors by DU-125530 cancels benefits obtained by enhancing pre-synaptic 5-hydroxytryptaminergic function.
RCT Entities:
BACKGROUND AND PURPOSE: The antidepressant efficacy of selective 5-HT reuptake inhibitors (SSRI) and other 5-HT-enhancing drugs is compromised by a negative feedback mechanism involving 5-HT(1A) autoreceptor activation by the excess 5-HT produced by these drugs in the somatodendritic region of 5-HT neurones. 5-HT(1A) receptor antagonists augment antidepressant-like effects in rodents by preventing this negative feedback, and the mixed β-adrenoceptor/5-HT(1A) receptor antagonist pindolol improves clinical antidepressant effects by preferentially interacting with 5-HT(1A) autoreceptors. However, it is unclear whether 5-HT(1A) receptor antagonists not discriminating between pre- and post-synaptic 5-HT(1A) receptors would be clinically effective. EXPERIMENTAL APPROACH: We characterized the pharmacological properties of the 5-HT(1A) receptor antagonist DU-125530 using receptor autoradiography, intracerebral microdialysis and electrophysiological recordings. Its capacity to accelerate/enhance the clinical effects of fluoxetine was assessed in a double-blind, randomized, 6 week placebo-controlled trial in 50 patients with major depression (clinicaltrials.gov identifier NCT01119430). KEY RESULTS:DU-125530 showed equal (low nM) potency to displace agonist and antagonist binding to pre- and post-synaptic 5-HT(1A) receptors in rat and human brain. It antagonized suppression of 5-hydroxytryptaminergic activity evoked by 8-OH-DPAT and SSRIs in vivo. DU-125530 augmented SSRI-induced increases in extracellular 5-HT as effectively as in mice lacking 5-HT(1A) receptors, indicating a silent, maximal occupancy of pre-synaptic 5-HT(1A) receptors at the dose used. However, DU-125530 addition to fluoxetine did not accelerate nor augment its antidepressant effects. CONCLUSIONS AND IMPLICATIONS: DU-125530 is an excellent pre- and post-synaptic 5-HT(1A) receptor antagonist. However, blockade of post-synaptic 5- HT(1A) receptors by DU-125530 cancels benefits obtained by enhancing pre-synaptic 5-hydroxytryptaminergic function.
Authors: Paul E Greenberg; Ronald C Kessler; Howard G Birnbaum; Stephanie A Leong; Sarah W Lowe; Patricia A Berglund; Patricia K Corey-Lisle Journal: J Clin Psychiatry Date: 2003-12 Impact factor: 4.384
Authors: Sylvie Lemonde; Gustavo Turecki; David Bakish; Lisheng Du; Pavel D Hrdina; Christopher D Bown; Adolfo Sequeira; Neena Kushwaha; Stephen J Morris; Ajoy Basak; Xiao-Ming Ou; Paul R Albert Journal: J Neurosci Date: 2003-09-24 Impact factor: 6.167
Authors: Jonathan G Bonchak; Jonathan M Eby; Kristin A Willenborg; David Chrobak; Steven W Henning; Anna Krzywiec; Steven L Johnson; I Caroline Le Poole Journal: Arch Biochem Biophys Date: 2014-08-14 Impact factor: 4.013
Authors: Mohammad Hadi Gharedaghi; Mohammad Seyedabadi; Jean-Eric Ghia; Ahmad Reza Dehpour; Reza Rahimian Journal: Exp Brain Res Date: 2013-11-14 Impact factor: 1.972
Authors: D Arnone; T Wise; C Walker; P J Cowen; O Howes; S Selvaraj Journal: Prog Neuropsychopharmacol Biol Psychiatry Date: 2018-02-01 Impact factor: 5.067
Authors: Karolina Pytka; Anna Partyka; Magdalena Jastrzębska-Więsek; Agata Siwek; Monika Głuch-Lutwin; Barbara Mordyl; Grzegorz Kazek; Anna Rapacz; Adrian Olczyk; Adam Gałuszka; Marian Błachuta; Anna Waszkielewicz; Henryk Marona; Jacek Sapa; Barbara Filipek; Anna Wesołowska Journal: PLoS One Date: 2015-11-10 Impact factor: 3.240